Research programme: intranasal hepatitis B vaccine - NanoBio

Drug Profile

Research programme: intranasal hepatitis B vaccine - NanoBio

Alternative Names: NB-007; Transmucosal hepatitis B vaccine - NanoBio

Latest Information Update: 22 Apr 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Michigan
  • Developer NanoBio Corporation; University of Michigan
  • Class Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Hepatitis B

Most Recent Events

  • 22 Apr 2010 Preclinical development is ongoing in USA
  • 13 Aug 2008 Immunogenicity & adverse events data from a preclinical trial in Hepatitis B released by NanoBio ,
  • 05 Apr 2007 Preclinical trials in Hepatitis B in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top